State Key Laboratory of Respiratory Diseases, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University, Guangzhou, China.
Front Immunol. 2021 Oct 1;12:738697. doi: 10.3389/fimmu.2021.738697. eCollection 2021.
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted the urgent need for novel therapies. Cell-based therapies, primarily using mesenchymal stromal cells (MSCs), have demonstrated safety and potential efficacy in the treatment of critical illness, particularly sepsis and acute respiratory distress syndrome (ARDS). However, there are limited preclinical data for MSCs in COVID-19. Recent studies have shown that MSCs could decrease inflammation, improve lung permeability, enhance microbe and alveolar fluid clearance, and promote lung epithelial and endothelial repair. In addition, MSC-based therapy has shown promising effects in preclinical studies and phase 1 clinical trials in sepsis and ARDS. Here, we review recent advances related to MSC-based therapy in the context of sepsis and ARDS and evaluate the potential value of MSCs as a therapeutic strategy for COVID-19.
新型冠状病毒病（COVID-19）大流行带来的严重呼吸后果促使人们迫切需要新的治疗方法。基于细胞的疗法主要使用间充质基质细胞（MSCs），已在治疗危重病，特别是脓毒症和急性呼吸窘迫综合征（ARDS）方面显示出安全性和潜在疗效。然而，关于 COVID-19 中 MSCs 的临床前数据有限。最近的研究表明，MSCs 可以减轻炎症，改善肺通透性，增强微生物和肺泡液清除，并促进肺上皮和内皮修复。此外，基于 MSC 的治疗在脓毒症和 ARDS 的临床前研究和 1 期临床试验中显示出有希望的效果。在这里，我们综述了与脓毒症和 ARDS 相关的基于 MSC 的治疗的最新进展，并评估了 MSCs 作为 COVID-19 治疗策略的潜在价值。
Zotero 插件